This selected index is a navigation aid, not a substitute for the current label. Approval is product-, formulation-, indication-, population-, and jurisdiction-specific. It does not confer status on a similarly named An entry with frequent visibility in the research-peptide ecosystem. Visibility is not endorsement, and marketed material is not assumed safe, sterile, authentic, or suitable for humans. 定义来源: Scope and selection methodology · 术语表 material and contains no preparation or regimen instructions.
How to use this index
Confirm all parts of an authorization statement together: active ingredient, named product and form, reviewed indication and population, jurisdiction, and record date. Then follow the short agency link to the authoritative record and recheck the current revision. An ingredient’s appearance in this table does not validate another product containing or claiming that ingredient.
Index fields: Ingredient, Class, Jurisdiction / status links, and Form / route. The complete source-linked table remains available without JavaScript.
Jurisdiction context: United States, European Union / EEA, and United Kingdom.
Active ingredient + product and form + indication and population + jurisdiction + as-of date → status statement. Same ingredient does not mean the same product claim.
Index
| Ingredient / example brand | Class | US label | EU / UK label | Form / route |
|---|---|---|---|---|
| Abaloparatide / Tymlos | Parathyroid-hormone receptor agonist | DailyMed ↗ | No link in this index | Administered into the tissue layer under the skin. 定义来源: Neutral gloss; usage context: Routes, devices, and absorption primer · 术语表 solution in a multi-use prefilled pen |
| Bivalirudin / Angiomax | Direct thrombin inhibitor | FDA label ↗ | No link in this index | Administered into a vein. 定义来源: Neutral gloss; usage context: Routes, devices, and absorption primer · 术语表 Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. 定义来源: Lyophilization, formulation, and stability primer · 术语表 presentation |
| Buserelin / Suprefact | GnRH agonist | No link in this index | UK eMC ↗ | SC solution or intranasal spray, product-specific |
| Calcitonin (salmon) / Miacalcin | Calcitonin analogue | DailyMed ↗ | UK eMC ↗ | SC / Administered into a muscle. 定义来源: Neutral gloss; usage context: Routes, devices, and absorption primer · 术语表 solution, named product-specific |
| Cetrorelix / Cetrotide | GnRH antagonist | DailyMed ↗ | EMA ↗ | SC lyophilized presentation |
| Degarelix / Firmagon | GnRH antagonist | DailyMed ↗ | EMA ↗ | SC lyophilized presentation |
| Desmopressin / DDAVP injection | Vasopressin analogue | DailyMed ↗ | National-register check needed | IV / SC solution, named product-specific |
| Dulaglutide / Trulicity | Expansion of the abbreviation used in the monographs: glucagon-like peptide-1 receptor agonist. The atlas does not define the pharmacology of this class; see the monograph for what is documented about a specific compound. 定义来源: Neutral gloss; the abbreviation is printed on the tirzepatide monograph but the atlas does not define the class pharmacology · 术语表 | DailyMed ↗ | EMA ↗ | SC solution in a single-use prefilled pen |
| Enfuvirtide / Fuzeon | HIV fusion inhibitor | FDA label ↗ | EMA ↗ | SC lyophilized presentation |
| Exenatide / Byetta | GLP-1 receptor agonist | DailyMed ↗ | EMA ↗ | SC solution in a multi-use prefilled pen |
| Glucagon / GlucaGen | Glucagon | FDA label ↗ | National-register check needed | SC / IM / IV lyophilized presentation |
| Goserelin / Zoladex | GnRH agonist | DailyMed ↗ | National-register check needed | SC depot implant in a prefilled device |
| Insulin aspart / NovoLog | Rapid-acting insulin | DailyMed ↗ | EMA ↗ | SC solution in vial, pen, or pump-compatible presentations |
| Insulin glargine / Lantus | Long-acting insulin | DailyMed ↗ | EMA ↗ | SC solution in vial or prefilled pen presentations |
| Lanreotide / Somatuline Depot | Somatostatin analogue | DailyMed ↗ | National-register check needed | Deep-SC prefilled syringe presentation |
| Leuprolide / Lupron Depot | GnRH agonist | DailyMed ↗ | National-register check needed | IM depot microsphere presentation |
| Liraglutide / Victoza | GLP-1 receptor agonist | DailyMed ↗ | EMA ↗ | SC solution in a multi-use prefilled pen |
| Octreotide / Sandostatin products | Somatostatin analogue | DailyMed injection ↗; DailyMed LAR ↗ | National-register check needed | SC / IV solution or IM depot presentation, product-specific |
| Pramlintide / Symlin | Amylin analogue | DailyMed ↗ | No link in this index | SC solution in a multi-use prefilled pen |
| Semaglutide / Ozempic | GLP-1 receptor agonist | DailyMed ↗ | EMA ↗ | SC solution in a multi-use prefilled pen |
| Somatropin / Genotropin | Growth hormone | DailyMed ↗ | National-register check needed | SC cartridge or lyophilized presentation, product-specific |
| Teriparatide / Forteo | Parathyroid-hormone analogue | DailyMed ↗ | EMA ↗ | SC solution in a multi-use prefilled pen |
| Tesamorelin / Egrifta WR | Growth-hormone-releasing-factor analogue | DailyMed ↗ | No link in this index | SC lyophilized presentation |
| Vasopressin / Vasostrict | Vasopressin | DailyMed ↗ | UK eMC ↗ | IV aqueous solution |
Limitations
The index is selected, not exhaustive, and was checked on the front-matter date.
A US authorization does not establish EU or UK authorization, and a centralized EU record is not the only route by which a medicine may be nationally authorized.
“No link in this index” means this table supplies no record; it is not a nonapproval statement. “National-register check needed” preserves the distinction between centralized and national records.
Links and labels change. Confirm the current named product, formulation, indication, population, revision date, and jurisdiction in the authoritative record.
Route and form are high-level identity fields only. They do not reproduce preparation, storage, regimen, or administration instructions.
Approval of an ingredient does not validate a An entry with frequent visibility in the research-peptide ecosystem. Visibility is not endorsement, and marketed material is not assumed safe, sterile, authentic, or suitable for humans. 定义来源: Scope and selection methodology · 术语表 material, compounded preparation, counterfeit, or unrelated product making a similar claim.
Sources
FDA Drugs@FDA Database. https://www.accessdata.fda.gov/scripts/cder/daf/
EMA Medicines Database. https://www.ema.europa.eu/en/medicines
UK Electronic Medicines Compendium (eMC). https://www.medicines.org.uk/emc
DailyMed (NIH). https://dailymed.nlm.nih.gov/dailymed/